Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 361

1.

Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam.

Cuong do D, Thorson A, Sönnerborg A, Hoa NP, Chuc NT, Phuc HD, Larsson M.

Scand J Infect Dis. 2012 Mar;44(3):201-8. doi: 10.3109/00365548.2011.631937. Epub 2011 Nov 28.

PMID:
22122590
2.

Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study.

Kouanda S, Meda IB, Nikiema L, Tiendrebeogo S, Doulougou B, Kaboré I, Sanou MJ, Greenwell F, Soudré R, Sondo B.

AIDS Care. 2012;24(4):478-90. doi: 10.1080/09540121.2011.630353. Epub 2011 Dec 7.

PMID:
22148973
3.

Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.

Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E.

AIDS. 2006 May 12;20(8):1181-9.

PMID:
16691070
4.

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, Thawornwan U, Suntisuklappon B, Nilkamhang S, Sungkanuparph S; TIME Study Team.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):377-83. doi: 10.1097/QAI.0b013e31825b5e06.

PMID:
22592586
5.
6.

Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.

Fregonese F, Collins IJ, Jourdain G, Lecoeur S, Cressey TR, Ngo-Giang-Houng N, Banchongkit S, Chutanunta A, Techapornroong M, Lallemant M; Program for HIV Prevention and Treatment Study Group.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):91-8. doi: 10.1097/QAI.0b013e31824bd33f.

PMID:
22293548
7.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
8.

Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.

De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AM, Buonomo E, Prosperi MC, Pedruzzi B, Noorjehan AM, Scarcella P, Liotta G, Palombi L.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):236-44. doi: 10.1097/QAI.0b013e31824276e9.

PMID:
22327246
9.
10.

Survival of HIV-infected patients after starting tuberculosis treatment: a prospective cohort study.

Maruza M, Albuquerque MF, Braga MC, Barbosa MT, Byington R, Coimbra I, Moura LV, Batista JD, Diniz GT, Miranda-Filho DB, Lacerda HR, Rodrigues LC, Ximenes RA.

Int J Tuberc Lung Dis. 2012 May;16(5):618-24. doi: 10.5588/ijtld.11.0110. Epub 2012 Mar 8.

PMID:
22410415
11.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
12.

Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam.

Huong DT, Bannister W, Phong PT, Kirk O, Peters L.

Int J STD AIDS. 2011 Nov;22(11):659-64. doi: 10.1258/ijsa.2011.010515.

PMID:
22096052
13.

[Survival and immune response of rural HIV/AIDS patients after free antiretroviral therapy].

Ding YY, Jia WQ, Wang JS, Dong SL, Yang QH, Zhou RY, Qu SX, Lu LX, Wei J, Qiao XC, Gao MY, Guo XL, Zhang TJ, Wu ZY, He N.

Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Dec;29(12):1176-80. Chinese.

PMID:
19173958
14.

Mortality and progression to AIDS after starting highly active antiretroviral therapy.

van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group.

AIDS. 2003 Oct 17;17(15):2227-36.

PMID:
14523280
15.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
16.

Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.

Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X.

AIDS. 2007 Nov 30;21(18):2483-91.

PMID:
18025885
17.

A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.

Piketty C, Weiss L, Assoumou L, Burgard M, Mélard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D; ANRS 116 SALTO Study Group.

J Med Virol. 2010 Nov;82(11):1819-28. doi: 10.1002/jmv.21907.

PMID:
20872707
18.

Treatment outcomes from the largest antiretroviral treatment program in Myanmar (Burma): a cohort analysis of retention after scale-up.

Sabapathy K, Ford N, Chan KN, Kyaw MK, Elema R, Smithuis F, Floyd S.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):e53-62. doi: 10.1097/QAI.0b013e31824d5689.

PMID:
22334069
19.
20.

Predictors of mortality among HIV-infected women in Kigali, Rwanda.

Lindan CP, Allen S, Serufilira A, Lifson AR, Van de Perre P, Chen-Rundle A, Batungwanayo J, Nsengumuremyi F, Bogaerts J, Hulley S.

Ann Intern Med. 1992 Feb 15;116(4):320-8.

PMID:
1733389

Supplemental Content

Support Center